Inmune Bio, Inc.
INMB evidence brief
What we can confirm
- BioSniper Score:
- 7.5 / 10
- Market Cap:
- $56.3M
- Lead Asset:
- cordstrom (Phase 3)
What it means
What to watch
Prepared research question
What matters most for INMB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INMB
Inmune Bio, Inc. (INMB) is a clinical-stage biotechnology company developing systemic therapies for rare diseases, neuroinflammation, and oncology, with a lead program (CORDStrom) for recessive dystrophic epidermolysis bullosa (RDEB) nearing regulatory submission.
Key risk: Cash runway risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$56.3M
Cash Runway
—
Lead Asset
cordstrom (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 5 clinical trials for Inmune Bio, Inc..
Inmune Bio, Inc. (INMB) is a clinical-stage biotechnology company developing systemic therapies for rare diseases, neuroinflammation, and oncology, with a lead program (CORDStrom) for recessive dystrophic epidermolysis bullosa (RDEB) nearing regulatory submission.
- Lead program CORDStrom targets RDEB, a devastating pediatric orphan disease with no approved systemic treatments; a pivotal trial has been completed and regulatory submissions (MAA in UK/EU, BLA with FDA) are targeted for 2026 [sec_mda · as of 2026-08-06][sec_mda · as of 2026-03-30].
- The company is advancing two other clinical-stage platforms: XPro1595 (neuroinflammation) and INKmune (oncology, nearing completion of a Phase II trial for mCRPC) [sec_mda · as of 2026-08-06].
- As of 2026-06-30, the company reported a net loss of -$1.3M and shareholders' equity of $20.4M [sec].
- Cash and cash equivalents were $21.4M as of March 31, 2026, which the company projects will be insufficient to sustain operations without additional financing [sec_mda · as of 2026-05-07].
- The company has never been profitable and has incurred losses each period since inception, with a net loss of $6.7M for the six months ended [sec_mda · as of 2026-08-06].
What works
- CORDStrom has completed a pivotal, blinded, randomized cross-over trial, positioning the company for regulatory submission and potential first-to-market systemic treatment for RDEB [sec_mda · as of 2026-08-06].
- The company has three distinct clinical-stage platforms (rare disease, neuroinflammation, oncology) addressing high unmet medical needs [sec_mda · as of 2026-08-06].
- Management has a clear regulatory pathway: MAA in UK/EU followed by BLA with FDA targeted for 2026 [sec_mda · as of 2026-03-30].
What to weigh
- The company has never been profitable and has incurred losses each period since inception, with substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-08-06].
- Cash and cash equivalents of $21.4M as of March 31, 2026 are projected to be insufficient to support operations, requiring additional financing through equity, debt, or partnerships [sec_mda · as of 2026-05-07].
- Regulatory approval for CORDStrom is uncertain; the process is lengthy, complex, and may require additional data, causing delays or denial [sec_mda · as of 2026-03-30].
- The company expects to continue incurring significant expenses and increasing operating losses for the foreseeable future, with no product candidates expected to be commercially available for several years, if ever [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
CORDStrom targets RDEB, a devastating pediatric orphan disease with no approved systemic treatments.
“B is a devastating pediatric orphan disease caused by mutations in the COL7A1 gene. This genetic deficiency leads to systemic complications, including highly debilitating skin blistering, chronic non-healing wounds, dysphagia, and failure to thrive.”
SEC MD&A · August 6, 2026
The company has never been profitable and has incurred losses each period since inception.
“we are not and have never been profitable and have incurred losses in each period since our inception, resulting in substantial doubt in our ability to continue as a going concern.”
SEC MD&A · August 6, 2026
Cash and cash equivalents were $21.4 million as of March 31, 2026, projected to be insufficient.
“Our cash and cash equivalents were $21.4 million and total current assets were $22.8 million at March 31, 2026, which the Company is projecting will be insufficient to su”
SEC MD&A · May 7, 2026
Regulatory submission for CORDStrom is targeted for 2026.
“We intend to file a Marketing Authorization Application ("MAA") in the United Kingdom and the European Union, followed by a Biologics License Application ("BLA") with the U.S. Food and Drug Administration ("FDA") targeted for 2026.”
SEC MD&A · March 30, 2026
Catalyst timeline
- 2020-06-15 · Phase1_Start: Phase1_Start: A Phase I Open-Label Dose Escalation Study Of Intravenous INKmune In Patients With Myelodysplastic Syndrome With Excess Blasts (MDS-EB-1/2 - MDS-CMML 1/2) Or Acute Myeloid Leukaemia (AML) — Initiation of Phase I trial for INKmune in MDS/AML; no recent update on this specific trial in the chunks.
- 2020-10-21 · Phase3_Start: Phase3_Start: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of INB03 in the Treatment of Participants With Pulmonary Complications From Coronavirus Disease (COVID-19) — Start of Phase III trial for INB03 in COVID-19 pulmonary complications; no recent update in the chunks.
- 2022-02-28 · Phase2_Start: Phase2_Start: A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation — Initiation of Phase II trial for XPro1595 in early Alzheimer's disease; no recent update in the chunks.
- 2023-02-21 · Phase2_Start: Phase2_Start: An Open Label Extension of XPro1595 in Patients With Alzheimer's Disease That Have Completed a Phase 1 or Phase 2 St — Start of open-label extension for XPro1595 in Alzheimer's; no recent update in the chunks.
Risks & what to watch (4)›
Key risks
- Cash runway risk — Cash of $21.4M as of March 31, 2026 projected insufficient to sustain operations; additional financing needed [sec_mda · as of 2026-05-07].
- Regulatory approval uncertainty — CORDStrom MAA/BLA may be delayed or denied; process is lengthy and unpredictable [sec_mda · as of 2026-03-30].
- No revenue, ongoing losses — Company has never been profitable; net loss of $6.7M for six months ended [sec_mda · as of 2026-08-06].
- Commercialization timeline — No product candidates expected to be commercially available for several years, if ever [sec_mda · as of 2026-08-06].
What to watch
- Regulatory submission of CORDStrom MAA in UK/EU and BLA with FDA targeted for 2026 [sec_mda · as of 2026-03-30].
- Completion of the open-label Phase II trial for INKmune in mCRPC [sec_mda · as of 2026-08-06].
- Company's ability to secure additional financing (equity, debt, partnerships) given projected cash insufficiency [sec_mda · as of 2026-05-07].
- Any updates on XPro1595 neuroinflammation program and its clinical progress [sec_mda · as of 2026-08-06].
Sources: Catalysts · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Inmune Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Inmune Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.32 · 0% dilution
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 16.9%
- Days to cover
- 6.4
- Shares short
- 3,425,591
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INMB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Inmune Bio, Inc.?
Inmune Bio, Inc. (INMB) is a clinical-stage biotechnology company developing systemic therapies for rare diseases, neuroinflammation, and oncology, with a lead program (CORDStrom) for recessive dystrophic epidermolysis bullosa (RDEB) nearing regulatory submission.
What is Inmune Bio, Inc.'s lead drug candidate?
Inmune Bio, Inc.'s most advanced tracked candidate is cordstrom (Phase 3) for Recessive Dystrophic Epidermolysis Bullosa (RDEB).
Who is the CEO of Inmune Bio, Inc.?
Mr. David J. Moss M.B.A. is the chief executive officer of Inmune Bio, Inc. (INMB).
Where is Inmune Bio, Inc. headquartered?
Inmune Bio, Inc. (INMB) is headquartered in Boca Raton, FL, United States.
What therapeutic areas does Inmune Bio, Inc. focus on?
Inmune Bio, Inc. develops therapies across Oncology, Gene Therapy, Neurology, Infectious Disease, Respiratory, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.